Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VK-2019 in Relapsed or Refractory EBV+ DLBCL
NCT06789159Phase 1Recruiting
- Start
- Aug 2026
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of VK-2019 in diffuse large B-cell lymphoma (DLBCL) (3 arms). Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Aug 2026; status: recruiting.
02
Drugs
VK-2019
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06789159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06789159.